Vaccination represents the primary public health measure to combat infectious diseases. However limitations of cold-chain storage, vaccine wastage and sharps-waste add unsustainable logistic costs to immunisation programmes. ImmuPatch is a dissolvable microneedle-based skin patch technology that is being designed to overcome these obstacles. Adenoviruses are one of the most potent vaccine platforms tested to date in humans and they are being developed to prevent diseases such as malaria, HIV and Ebola virus. The ImmuPatch research group have developed methods of stably formulating vaccines, including adenovirus-based vaccines, into microneedles to produce immunogenic vaccine-containing dissolvable microneedles (DMN), which release the vaccine into the skin subsequent to their insertion. These stable vaccine-loaded DMN patches are therefore designed to overcome logistic immunization issues. In this project I will quantify how much of the adenovirus vaccine is delivered into ex vivo human skin samples. First, I will develop a method to precisely quantify adenoviral DNA and optimise its extraction from the skin. Subsequently I will determine how much of the adenovirus vaccine is delivered into the skin by the DMN patch, compared to on the skin or remaining on the adhesive patch and also, to what layer in the skin it is located. Finally, I will examine how the skin’s immune system responds when this vaccine-loaded DMN patch is used. This project will develop important methods and data that will be used in the future during its clinical translation. It also provides a unique experience for me to better understand how biomedical research is conducted.